| 1 |
34706060 | Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. | 2022 Feb 15 |
1 |
| 2 |
32052681 | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. | 2021 |
1 |
| 3 |
33307872 | New insights into the clinical management of advanced gastrointestinal stromal tumors. | 2021 Mar |
1 |
| 4 |
31608707 | The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. | 2020 Jan |
1 |
| 5 |
32207565 | Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. | 2020 Jun |
1 |
| 6 |
29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May |
1 |
| 7 |
30069758 | Regorafenib. | 2018 |
2 |
| 8 |
26651387 | The safety of regorafenib for the treatment of gastrointestinal stromal tumors. | 2016 Jan |
1 |
| 9 |
26865419 | Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. | 2016 May |
1 |
| 10 |
27045179 | Comparison of the crystal structures of the potent anticancer and anti-angiogenic agent regorafenib and its monohydrate. | 2016 Apr |
1 |
| 11 |
25336117 | A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib. | 2015 Jan |
1 |
| 12 |
24559322 | Regorafenib in metastatic colorectal cancer. | 2014 Mar |
1 |
| 13 |
24756792 | Regorafenib. | 2014 |
1 |
| 14 |
23435872 | Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor. | 2013 Jun |
2 |
| 15 |
22421192 | A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. | 2012 May 1 |
1 |
| 16 |
22577890 | Regorafenib for cancer. | 2012 Jun |
2 |
| 17 |
22614970 | Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. | 2012 Jul 1 |
2 |
| 18 |
21170960 | Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. | 2011 Jul 1 |
1 |